RadNet to Host Q4 2025 Financial Results Conference Call on March 2, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy RDNT?
Source: Newsfilter
- Conference Call Announcement: RadNet will host a conference call on March 2, 2026, at 7:30 AM PT to discuss its Q4 2025 financial results, which is expected to attract investor interest and could impact stock performance.
- Participation Details: Investors can join the call by dialing 844-826-3035, with international callers using 412-317-5195, ensuring that global investors have access to the latest financial information, thereby enhancing transparency.
- Webcast and Replay Availability: The call will feature simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1753363&tp_key=503d78aa96, allowing investors who cannot attend live to access the information at their convenience, improving information accessibility.
- Company Overview: RadNet is a leading provider of freestanding diagnostic imaging services in the U.S., with over 12,000 employees and significant annual imaging revenue, highlighting its strong competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDNT
Wall Street analysts forecast RDNT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 72.580
Low
86.00
Averages
90.17
High
95.00
Current: 72.580
Low
86.00
Averages
90.17
High
95.00
About RDNT
RadNet, Inc. is a national provider of fixed-site diagnostic imaging services in the United States. The Company has a network of 407 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. It provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. It is also a provider of AI-powered breast health solutions.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

- Acquisition Announcement: RadNet will hold a conference call on March 5, 2026, to detail its acquisition of Gleamer SAS, which is expected to enhance its competitive position in the medical imaging sector and drive future revenue growth.
- Digital Health Strategy: During the call, RadNet will share insights into its digital health strategy, particularly focusing on AI-powered health informatics solutions offered under the DeepHealth brand, aimed at improving clinical outcomes and operational efficiency in imaging.
- Investor Engagement Opportunity: Investors will have the chance to ask questions during the call, which not only enhances investor confidence but also provides direct feedback to management, fostering better communication between the company and its investors.
- Global Market Impact: Gleamer's AI solutions have analyzed over 30 million exams across more than 2,250 locations in 44 countries, and RadNet's acquisition is set to further expand its global market share, enhancing its influence in the medical imaging industry.
See More
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, significantly enhancing VentriPoint's market opportunities.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' demand for economic value alongside clinical accuracy, positioning VentriPoint's VMS+™ system to meet this critical need.
- Strategic Partnership: VentriPoint has signed a commercial agreement with LG Consulting Solutions to support the deployment of its VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of the technology.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform aimed at supporting hospital engagement, clinician training, and economic value assessments, thereby accelerating the adoption of new medical technologies.
See More
- Record Earnings: RadNet achieved a record revenue of $547.7 million in Q4 2025, reflecting a 14.8% year-over-year increase, while adjusted EBITDA reached $87.7 million, up 16.9%, indicating robust market demand and operational efficiency.
- Digital Health Surge: The Digital Health segment saw a remarkable 48.2% revenue growth to $27.9 million, with adjusted EBITDA of $4.9 million, showcasing the company's rapid expansion in digital healthcare and future growth potential, with ARR expected to approach $140 million by 2026.
- Gleamer Acquisition: RadNet completed the acquisition of Paris-based Gleamer, enhancing its leadership in global radiology clinical AI solutions, bringing over 700 customer contracts and expected to contribute approximately $30 million to future revenue growth.
- 2026 Outlook: The company anticipates imaging center revenue growth of 17% to 19% in 2026, with Digital Health revenue growth projected between 45% and 55%, reflecting management's confidence in future performance and emphasis on AI technology.
See More
- Mixed Market Performance: On Monday, the S&P 500 closed up 0.04%, while the Dow Jones Industrial Average fell 0.15%, and the Nasdaq 100 rose 0.13%, reflecting a divergence in market sentiment influenced by the ongoing war in Iran, with increased demand for defense and energy stocks.
- Surge in Oil Prices: WTI crude oil prices soared over 6% to an 8.25-month high following Iran's attack on oil tankers, which is expected to elevate inflation expectations and impact the overall economic environment and investor confidence.
- Strong Manufacturing Index: The US February ISM manufacturing index unexpectedly rose to 52.4, surpassing the market expectation of 51.5, indicating economic resilience that could influence the Federal Reserve's monetary policy direction, leading to shifts in future rate hike expectations.
- Optimistic Earnings Outlook: More than 90% of S&P 500 companies have reported earnings, with 73% exceeding expectations, and Q4 earnings growth is projected at 8.4%, providing market support despite geopolitical risks.
See More
- Conference Details: RadNet, Inc.'s CFO Mark Stolper will present at the Raymond James 47th Annual Institutional Investors Conference on March 3, 2026, at 2:15 p.m. Eastern Time in Orlando, Florida, highlighting the company's leadership in diagnostic imaging services.
- Live Webcast: The presentation will be available via live webcast, allowing investors unable to attend in person to stay informed about the company's latest developments through the provided link.
- Company Overview: RadNet is a leading independent provider of diagnostic imaging services in the U.S., employing over 11,000 team members across states like California, Texas, and New York, with significant annual imaging revenue and a large network of centers.
- Technological Innovation: RadNet also offers radiology information technology and AI solutions under the DeepHealth brand, enhancing its competitive edge in the diagnostic imaging industry to meet the growing demand for efficient and accurate services.
See More





